A Randomized, Double-Blind, Placebo-Controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients

COMMENTED

Type 2 Diabetes

Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial

★ 3 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Diabetes Care

Dubourg J, Fouqueray P, Thang C, Grouin JM, Ueki K

doi: 10.2337/dc20-0763

Diabetes - GeneralType 1 DiabetesGlycemic Control

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial

Lancet Diabetes Endocrinol.

Petrie JR, Chaturvedi N, Ford I, Brouwers MCGJ, Greenlaw N, Tillin T, Hramiak I, Hughes AD, Jenkins AJ, Klein BEK, Klein R, Ooi TC, Rossing P, Stehouwer CDA, Sattar N, Colhoun HM; REMOVAL Study Group

doi: 10.1016/

Type 2 Diabetes

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

Diabetes Care.

Kahl S, Gancheva S, Straßburger K, Herder C, Machann J, Katsuyama H, Kabisch S, Henkel E, Kopf S, Lagerpusch M, Kantartzis K, Kupriyanova Y, Markgraf D, van Gemert T, Knebel B, Wolkersdorfer MF, Kuss O, Hwang JH, Bornstein SR, Kasperk C, Stefan N, Pfeiffer A, Birkenfeld AL, Roden M

doi: 10.2337/dc19-0641.

Type 2 Diabetes

Liraglutide as add-on to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial

Diabetes Obes Metab.

Blonde L, Belousova L, Fainberg U, Garcia-Hernandez PA, Jain SM, Kaltoft MS, Mosenzon O, Nafach J, Palle MS, Rea R

doi: 10.1111/dom.13978.

Type 1 DiabetesObesity and Bariatric Surgery

Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial - a randomized, double-blinded, placebo-controlled trial

Diabetes Obes Metab.

Dejgaard TF, Schmidt S, Frandsen CS, Vistisen D, Madsbad S, Andersen HU, Nørgaard K

doi: 10.1111/dom.13911.

Further Publications

Henagliflozin Monotherapy in Patients with Type 2 Diabetes Inadequately Controlled on Diet and Exercise: A Randomized, Double-blind, Placebo-controlled, Phase 3 Trial

Diabetes Obes Metab

Lu J, Fu L, Li Y, Geng J, Qin L, Ping L, Zheng H, Sun Z, Li Y, Zhang L, Sun Y, Chen D, Qin G, Weiping L, Guo Y, Zhang Y, Liu H, Zhang T, Zou J

doi: 10.1111/dom.14314

Type 1 DiabetesGlycemic Control

Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial

★ 0 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Lancet Diabetes Endocrinol.

Johansen NJ, Dejgaard TF, Lund A, Schlüntz C, Frandsen CS, Forman JL, Wewer Albrechtsen NJ, Holst JJ, Pedersen-Bjergaard U, Madsbad S, Vilsbøll T, Andersen HU, Knop FK

doi: 10.1016/S2213-8587(20)30030-9.

Type 1 Diabetes

Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial

★ 1 Recommended by Prof. emer. Dr Ulrich Keller, Faculty Member

United European Gastroenterol J.

Wegeberg AL, Hansen CS, Farmer AD, Karmisholt JS, Drewes AM, Jakobsen PE, Brock B, Brock C

doi: 10.1177/2050640620925968.

Type 2 Diabetes

Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial

Diabetes Obes Metab

Weng J, Zeng L, Zhang Y, Qu S, Wang X, Li P, Fu L, Ma B, Ye S, Sun J, Lu W, Liu Z, Chen D, Cheng Z, Liu H, Zhang T, Zou J

doi: 10.1111/dom.14389

Related content

Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

Liraglutide as add-on to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial

Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial - a randomized, double-blinded, placebo-controlled trial

Henagliflozin Monotherapy in Patients with Type 2 Diabetes Inadequately Controlled on Diet and Exercise: A Randomized, Double-blind, Placebo-controlled, Phase 3 Trial

Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial

Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial

Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial